If youve been struggling to lose the stubborn weight that just wont budge, Im sure the thought of GLP-1 medications has crossed your mind a time or two
for example, ingestible electronic capsules able to monitor microbial fermentations directly in the gut ( Funding This work was supported by Novo Nordisk Foundation (Grant no
In 2020, Ro switched to obesity management and, after Wegovy was approved by the Food and Drug Adminstration the following year, Reitano said patient inquiries started pouring in by the "tens of thousands." Now, Ro is shoveling marketing dollars into its GLP-1 program from digital ads, TV commercials and posters lining subway stations, to influencer campaigns featuring patients such as Beard
At maximum doses, the two medications now produce very similar results: Wegovy 7.2 mg: 20.7% average weight loss (STEP UP trial) 2 Mounjaro 15 mg: 20.2% average weight loss (SURMOUNT-5 trial) 1 This means that if maximum weight loss is your primary goal, both medications can now achieve comparable results when used at their highest doses
276,277 Long-term adverse effects of KD include elevated cardiovascular risks with poor cholesterol profiles and nephrolithiasis, likely due to the metabolic effects of the KD, such as uric acidemia, hypocitraturia, hypercalciuria, aciduria, growth retardation, decreased bone mineral density, anemia, and neuropathy, 276,277 and are usually monitored during follow-up
Cost matters when making health decisions, but so does knowing that what you inject contains what the label says it contains
